Allyx Therapeutics, Inc.

Biotechnology · NEW HAVEN, CT

BiotechnologySEC Form D

Allyx Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on May 11, 2026, reporting $26,427,730 raised toward a $29,999,999 offering.

Incorporated in Delaware and based in NEW HAVEN, CT, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Allyx Therapeutics, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Stephen BlochExecutive Officer · Director
  • Stephen StrittmatterDirector
  • Paul FonteyneDirector
  • Gregory P HoDirector
  • Robert A BettigoleDirector
  • Timothy SiegertExecutive Officer
  • Kevin L. RakinDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$10.0MRaised

Senti Biosciences Holdings, Inc.

BiotechnologySouth San Francisco, CA
May 20, 2026View SEC Form D
Allyx Therapeutics, Inc. raised $26.4M — SEC Form D